Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
| 제품번호 | 종 | 제품 설명 | 구조 | 순도 | 특징 |
|---|---|---|---|---|---|
| PGF-H52G3 | Human | Human PlGF-1 Protein, GST Tag |  |
||
| PGF-H5255 | Human | Human PLGF-3 Protein, Fc Tag (MALS verified) |  |
|
|
| PGF-H5256 | Human | Human PlGF-1 Protein, Fc Tag (MALS verified) |  |
|
|
| PGF-H52H5 | Human | Human PlGF-1 Protein, His Tag (MALS verified) |  |
|
|
| PGF-M52H0 | Mouse | Mouse PLGF / PGF Protein, His Tag |  |
|
|
| PGF-R52H0 | Rhesus macaque | Rhesus macaque PLGF / PGF Protein, His Tag |  |
|
|
| PGF-H5229 | Human | Human PlGF-2 Protein, His Tag |  |
|
Immobilized Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) at 2 μg/mL (100 μL/well) can bind Human PlGF-1 Protein, Fc Tag (Cat. No. PGF-H5256) with a linear range of 0.1-3 ng/mL (QC tested).
The purity of Human PLGF-3 Protein, Fc Tag (Cat. No. PGF-H5255) is more than 85% and the molecular weight of this protein is around 115-130 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ziv-aflibercept | BAY-865321; AVE-0005 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Zaltrap | Japan | Colorectal Neoplasms | Sanofi | 2012-08-03 | Lymphoma; Urethral Neoplasms; Breast Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Carcinoma, Mucoepidermoid; Genital Neoplasms, Female; Gliosarcoma; Astrocytoma; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Ureteral Neoplasms; Peritoneal Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Uterine Neoplasms; Endometrial Neoplasms; Glioma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Thyroid Neoplasms; Retinal Vein Occlusion; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Leiomyosarcoma; Solid tumours; Multiple Endocrine Neoplasia Type 1; Leukemia; Rectal Neoplasms; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Ovarian Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Carcinoma, Papillary; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Ascites; Lung Diseases; Adenoc | Details |
| Aflibercept | BAT-86-5321; BAY-865321 | Approved | Regeneron Pharmaceuticals Inc, Bayer AG | Eylea | Japan | Retinopathy of Prematurity | Bayer Yakuhin Ltd | 2011-11-18 | Diabetic macular oedema; Corneal Neovascularization; Choroidal Neovascularization; Retinal Vein Occlusion; Carcinoma, Non-Small-Cell Lung; Diabetic Retinopathy; Macular Degeneration; Retinopathy of Prematurity; Neoplasm Metastasis; Lymphoma, Non-Hodgkin; Retinal Degeneration; Eye Diseases; Vitreous Hemorrhage; Diabetes Complications; Colorectal Neoplasms; Retinitis Pigmentosa; Diabetes Mellitus, Type 1; Wet Macular Degeneration; Prostatic Neoplasms; Retinal Diseases; Multiple Myeloma; Myopia, Degenerative; Central Serous Chorioretinopathy; Colonic Neoplasms; Neoplasms; Choroid Diseases; Rectal Neoplasms; Glaucoma, Neovascular; Macular Edema; Diabetes Mellitus, Type 2; Cataract | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ziv-aflibercept biosimiliar (Boan Biopharma) | LY-01012; BA-1103 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Colorectal Neoplasms | Details |
| Aflibercept biosimilar (Amgen) | ABP-938 | Phase 2 Clinical | Amgen Inc | Macular Degeneration | Details |
| Aflibercept biosimilar (Zein Bioteccnology) | Phase 1 Clinical | Zein Bioteccnology Co Ltd | Diabetic macular oedema | Details | |
| Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Sam Chun Dang Pharm Co Ltd | Details | ||
| FYB-203 | FYB-203 | Formycon | Details | ||
| Aflibercept biosimilar (Mabwell) | 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Diabetic macular oedema | Details |
| CT-P42 | CT-P42 | Phase 3 Clinical | Celltrion Inc | Diabetic macular oedema | Details |
| Aflibercept Biosimilar(Alvotech Swiss) | AVT-06 | Phase 3 Clinical | Alvotech Swiss Ag | Macular Degeneration | Details |
| Aflibercept biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
| Anti-placental growth factor monoclonal antibody | αPlGF; R-7334; TB-403; RG-7334; THR-317; RO-5323441 | Phase 2 Clinical | Thrombogenics, Bioinvent International Ab | Solid tumours; Retinal Telangiectasis; Ovarian Neoplasms; Medulloblastoma; Macular Edema; Glioblastoma; Colorectal Neoplasms; Diabetic Retinopathy; Carcinoma, Hepatocellular; Diabetes Mellitus; Macular Degeneration | Details |
| Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Phase 3 Clinical | Mylan Nv, Momenta | Diabetic macular oedema | Details |
| 4D-150 | 4D-150 | Phase 2 Clinical | 4d Molecular Therapeutics Inc | Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy | Details |
| Aflibercept Biosimilar (Boan Biopharma/Luye Pharma） | LY-09004; BA-9101; OT-702 | Phase 3 Clinical | Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
| Aflibercept biosimilar (Samsung Bioepis) | SB-15 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Macular Degeneration | Details |
This web search service is supported by Google Inc.
A-Z
